Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmesis International's quarterly market cap
declined
from Dec. 2024 (S$18.23 Mil) to Jun. 2025 (S$15.85 Mil) and
declined
from Jun. 2025 (S$15.85 Mil) to Dec. 2025 (S$12.05 Mil).
Pharmesis International's annual market cap
increased
from Dec. 2023 (S$2.70 Mil) to Dec. 2024 (S$18.23 Mil) but then
declined
from Dec. 2024 (S$18.23 Mil) to Dec. 2025 (S$12.05 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Pharmesis International's Enterprise Value for Today is S$5.55 Mil.
Pharmesis International (SGX:BFK) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Pharmesis International Market Cap Related Terms
Pharmesis International Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Pharmesis International's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmesis International Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pharmesis International's Market Cap distribution charts can be found below:
* The bar in red indicates where Pharmesis International's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Pharmesis International's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmesis International (SGX:BFK) has a Market Cap of S$3.39 Mil as of Aug. 08, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Pharmesis International and its competitors. According to the industry distribution chart, Pharmesis International ranks #956 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 93.5%.
Is Pharmesis International's Market Cap too high?
Pharmesis International's current Market Cap is S$3.39 Mil. Based on the distribution chart, Pharmesis International ranks #956 out of 1023 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pharmesis International has a GF Score™ of 31/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmesis International's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Pharmesis International ranks #956 out of 1023 companies for Market Cap. This places Pharmesis International in the lower half of its industry. The industry median Market Cap is 219.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 219.20, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Pharmesis International and its competitors. For the Drug Manufacturers industry, the median Market Cap is 219.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmesis International's current Market Cap is S$3.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmesis International stock overvalued right now?
Based on GuruFocus' analysis, Pharmesis International (SGX:BFK) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.09, compared to a current price of S$0.11 — trading 18.9% above its estimated fair value. The current Market Cap is S$3.39 Mil. Pharmesis International's overall GF Score™ is 31/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Pharmesis International (SGX:BFK), the current Market Cap is S$3.39 Mil as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmesis International (SGX:BFK) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmesis International stock appears to be overvalued.
The current stock price of S$0.11 is trading 18.9% above its estimated GF Value™ of S$0.09.
GuruFocus considers Pharmesis International to be Modestly Overvalued.
Key valuation signals for SGX:BFK:
Market Cap: S$3.39 Mil
GF Value™: S$0.09 vs. price of S$0.11 (18.9% above fair value)
No single metric tells the full story. See the SGX:BFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs/TCH Procurement, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs/IP rental, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which derives maximum revenue, refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
31GF Score
Get the complete analysis for SGX:BFK
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:BFK has been successfully added to your 
